IDH2 and cancer: The identification of an IDH2 mutation in a carotid body PGL not only broadens the understanding of these mutations in human cancers (particularly PGL), but it also highlights the role of metabolic deficiency in tumorigenesis of these tumors, implying possible therapeutic regimen by targeting the distinctive metabolic signature.